Halcinonide

CHEMBL1200845 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
455.0 g/mol
LogP
3.6
Phase
4

This potent topical corticosteroid is used to treat inflammatory skin conditions such as psoriasis, eczema, and dermatitis by reducing redness, itching, and swelling. It works by suppressing the local immune response and decreasing the production of inflammatory chemicals in the skin. It should be used sparingly and for short periods on sensitive skin areas.

Masse moléculaire

455,0000 g/mol

LogP

3,60

TPSA

72,80 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1

InChI

InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1

Molecular Formula

C24H32ClFO5

HBD / HBA

1 / 6

Liaisons Rotatives

2

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This potent topical corticosteroid is used to treat inflammatory skin conditions such as psoriasis, eczema, and dermatitis by reducing redness, itching, and swelling. It works by suppressing the local immune response and decreasing the production of inflammatory chemicals in the skin. It should be used sparingly and for short periods on sensitive skin areas.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Halcinonide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200845. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 443943. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.